Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE ISSUED NOVEMBER 14, 2016 - MABVAX THERAPEUTICS HOLDINGS, INC. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 14,
2016
MABVAX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
000-31265
|
|
93-0987903
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
11535 Sorrento Valley Rd., Suite 400
San Diego, CA 92121
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code:
(858) 259-9405
N/A
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
|
ITEM
7.01
|
REGULATION
FD DISCLOSURE
|
|
ITEM
8.01
|
OTHER
EVENTS
|
On November 14, 2016, MabVax Therapeutics Holdings, Inc. (the
“Company”) issued a press release that reported on
interim safety and imaging results from two phase I clinical trials
in the Company’s HuMab-5B1 antibody development program. The
press release is attached hereto as Exhibit 99.1.
The
Company also announced that it would hold a conference call to
discuss both the third quarter financial results and interim safety
and imaging results from the two phase I clinical results at the
following date and time:
When:
November 14, 2016, 4:15 p.m. EST
Dial-in:
(877) 407-8293 or (201) 689-8349
Conference
ID: MabVax Therapeutics Third Quarter 2016 Conference
Call
A
replay of the conference call will be available for 2 weeks shortly
after the call. To access the replay, please dial
877-660-6853 or 201-612-7415. Conference ID:
13649739.
The information in this report, including Exhibit 99.1 hereto, is
being furnished and shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, nor shall it be incorporated by reference into any
registration statement or other document pursuant to the Securities
Act of 1933, as amended, except as expressly set forth in such
filing.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
(d) Exhibits.
The exhibit listed in the following Exhibit Index is furnished with
this Current Report on Form 8-K.
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Press
release issued November 14, 2016
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
MABVAX
THERAPEUTICS HOLDINGS, INC.
|
|
|
|
|
|
|
|
|
Dated:
November 14,
2016
|
By:
|
/s/ Gregory Hanson
|
|
|
|
|
Gregory
Hanson
|
|
|
|
|
Chief
Financial Officer
|
|